期刊文献+

利拉鲁肽联合甘精胰岛素治疗预混胰岛素血糖控制不佳2型糖尿病患者的临床观察 被引量:23

下载PDF
导出
摘要 目的:观察评价利拉鲁肽联合甘精胰岛素治疗预混胰岛素血糖控制不佳2型糖尿病患者的疗效。方法:预混胰岛素血糖控制不佳2型糖尿病患者60例随机分为治疗组(利拉鲁肽联合甘精胰岛素治疗)和对照组(甘精胰岛素联合门冬胰岛素治疗)。比较治疗前后2组患者FBG、2hPG、HbA1c、BMI、低血糖发生次数以及患者满意度。结果:2组治疗12周后FBG、2hPG、HbA1c均较治疗前明显下降(P<0.05),但两组之间差异无统计学意义(P>0.05)。治疗组治疗12周后BMI明显低于治疗前(P<0.05),而对照组治疗前后BMI差异无统计学意义(P>0.05)。治疗组发生症状性低血糖次数明显少于对照组(P<0.01),患者满意度高。结论:利拉鲁肽联合甘精胰岛素可有效控制预混胰岛素血糖控制不佳2型糖尿病患者血糖,并且能明显降低BMI和低血糖发生次数,依从性较高。
机构地区 解放军
出处 《实用医学杂志》 CAS 北大核心 2013年第19期3227-3229,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献10

二级参考文献52

  • 1周岩,吴大方,陈域,姬秋和,王博,江玲.144例糖尿病合并胆石症围手术期胰岛素泵强化治疗的临床观察[J].中国糖尿病杂志,2006,14(1):29-30. 被引量:29
  • 2Holst JJ.Physiol Rev,2007,87:1409-1439.
  • 3Marre M,Shaw J,Brandle M,et al.Diabet Med,2009,26(3):268-278.
  • 4Nauck M,Frid A,Hermansen K,et al.Diabetes Care,2009,32(1):84-90.
  • 5Zinman B,Gerich J,Buse JB,et al.Diabetes Care,2009,32(7):1224-1230.
  • 6Russell-Jones D,Vaag A,Schmitz O,et al.Diabetologia,2009,52(10):2046-2055.
  • 7Blonde L,Russell-Jones D.Diabetes Obes Metab,2009,s3:26-34.
  • 8Merani S,Truong W,Emamaullee JA,et al.Endocrinology,2008,149(9):4322-4328.
  • 9Stephens JW,Bain SC.Expert Opin Drug Saf,2007,6(4):417-422.
  • 10Bell GI, Sanchez-pescador R, Laybourn PJ, et al. Exon duplication and divergene in the human preproglueagoon gene [J]. Nature, 1983,304(5924) :368-371.

共引文献33

同被引文献173

  • 1辛婧,沈亚非,邓飞.达格列净联合胰岛素强化治疗血糖控制不佳2型糖尿病的临床研究[J].中国实用医刊,2019,46(19):93-96. 被引量:17
  • 2唐祝奇,崔世维,朱晓晖,印彤,王粹芳.空腹和餐后2h C肽在评估2型糖尿病胰岛β细胞功能中的作用[J].中国老年学杂志,2014,34(12):3251-3252. 被引量:9
  • 3Kondo Y,Satoh S,Nagakura J,et al.Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes[J].J Diabetes Investig,2013,4(6):571-575.
  • 4Burgess CP, Bailie RS, Connors CM, et al. Early identifi-- cation and preventive care for elevated cardiovascular dis- ease risk within a remote Australian Aboriginal primary health care service[J]. BMC Health Serv Res, 2011 , 11 (1) :24.
  • 5Janka HU,Plewe G.Riddle MC,et al. Comparison of bas- al insulin added to oral agents versus twice-daily premzed insulin as initial insulin @,.erapy ror type 2 diabetes[J]. Di- abetes Care,2005,28(2) :254-259.
  • 6ho H,Abe M,Antoku S,et al. Effects of switching from prandlal premixed insulin therapy to basal plus two times bolus insulin tkerapy on glycemic control and quality of life in patients with type 2 diabetes mellitus[J]. Diug Des Dev Ther,2014,8(2) :391--396.
  • 7Gallwitz B, BBhmer M, Segiet T, et al. Exenatlde twice daily versus premixed insulin aspart 70/30 in metformin- treated patients with type 2 diabetes: a randomized 26- week study on glycemic control and hypoglycemia[J]. Di- abetes Care,2011,34(3) :604-606.
  • 8Handelsman Y,Bloomgarden ZT, Grunberger G, et al. A merican association of clinical endocrinologists and ameri can college of endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan- 2015[J]. Endocr Pract,2015,21 Suppl 1 : 1-87.
  • 9Silva MA,Cau SB,Lopes RA,et al.Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2diabetes mellitus[J].Clin Sci(Lond),2015,129(7):533-545.
  • 10Talebpour M,Talebpour A,Barzin G,et al.Effects of laparoscopic gastric plication(LGP)in patients with type 2 diabetes,one year follow-up[J].J Diabetes Metab Disord,2015,14:60.

引证文献23

二级引证文献179

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部